Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT03233724
What this trial is testing

Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas

Who this might be right for
Carcinoma, Non-Small-Cell LungLung CancerNon-Small Cell Lung Cancer+2 more
National Cancer Institute (NCI) 9
Post-approval studies (Phase 4)Study completedNCT01203917
What this trial is testing

Efficacy, Safety, Tolerability of Gefitinib as 1st Line in Caucasian Patients With EGFR Mutation Positive Advanced NSCLC

Who this might be right for
Caucasian Patients With EGFR Mutation Positive Advanced NSCLC
AstraZeneca 1,060
Testing effectiveness (Phase 2)Study completedNCT05775289
What this trial is testing

Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Hoffmann-La Roche 182
Testing effectiveness (Phase 2)Looking for participantsNCT07488676
What this trial is testing

ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

Who this might be right for
Gastric or Gastro-esophageal Junction (GEJ) AdenocarcinomaPancreatic Adenocarcinoma
Astellas Pharma Global Development, Inc. 150
Large-scale testing (Phase 3)Looking for participantsNCT06674343
What this trial is testing

Furmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical Mutations

Who this might be right for
Advanced or Metastatic Non-small Cell Lung Cancer
Peking Union Medical College Hospital 144
Large-scale testing (Phase 3)Active Not RecruitingNCT05499390
What this trial is testing

AK112 in Advanced Non-Small Cell Lung Cancer

Who this might be right for
Advanced Non-small-cell Lung Cancer
Akeso 398
Testing effectiveness (Phase 2)Active Not RecruitingNCT04036682
What this trial is testing

A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung CancerEGFR Exon 20 Mutation
Cullinan Therapeutics Inc. 284
Early research (Phase 1)Ended earlyNCT06364696
What this trial is testing

Find a Suitable Dose of ASP4396 in Adults With Solid Tumors

Who this might be right for
Solid Tumor
Astellas Pharma Inc 60
Not applicableNot Yet RecruitingNCT07599007
What this trial is testing

Repotrectinib Post-Marketing Surveillance in Korean Patients With ROS1-Positive Non-Small Cell Lung Cancer (NSCLC) or Solid Tumors Harboring a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion

Who this might be right for
Non-Small Cell Lung Cancer
Bristol-Myers Squibb 10
Testing effectiveness (Phase 2)Active Not RecruitingNCT06827145
What this trial is testing

Combination of Vebreltinib and Osimertinib in Patients with EGFR 21 L858R Mutation Advanced NSCLC

Who this might be right for
Non-Small-Cell Lung Cancer
National Cancer Center, China 30
Testing effectiveness (Phase 2)Study completedNCT02179671
What this trial is testing

Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

Who this might be right for
Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (Stage IIIB-IV)
AstraZeneca 32
Testing effectiveness (Phase 2)Ended earlyNCT03318939
What this trial is testing

Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation

Who this might be right for
NSCLC
Spectrum Pharmaceuticals, Inc 648
Testing effectiveness (Phase 2)Study completedNCT01529112
What this trial is testing

A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments

Who this might be right for
Non-Small Cell Lung Cancer
Eisai Inc. 135
Testing effectiveness (Phase 2)Study completedNCT03548467
What this trial is testing

Evaluate Safety and Efficacy of Multiple Dosing With VB10.NEO and Bempegaldesleukin (NKTR-214) Immunotherapy in Patients With Locally Advanced or Metastatic Cancer

Who this might be right for
Locally Advanced or Metastatic Solid Tumours
Nykode Therapeutics ASA 41
Testing effectiveness (Phase 2)Study completedNCT00284141
What this trial is testing

Study of AVE0005 (VEGF Trap) in Locally Advanced or Metastatic Platinum- and Erlotinib- Resistant Non-small-cell-lung Adenocarcinoma

Who this might be right for
Pulmonary DiseasesNeoplasms, Lung
Sanofi 98
Large-scale testing (Phase 3)Looking for participantsNCT07050043
What this trial is testing

Low Dose Nivolumab With Chemotherapy vs Standard Chemotherapy as First-Line Treatment in Advanced or Metastatic NSCLC

Who this might be right for
NSCLC (Non-small Cell Lung Carcinoma)First Line TherapyLocally Advanced/Metastatic NSCLC
Dr Arvindran A/L Alaga 123
Large-scale testing (Phase 3)Active Not RecruitingNCT06472076
What this trial is testing

Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)

Who this might be right for
Lung Cancer, Non-Small Cell
GlaxoSmithKline 88
Testing effectiveness (Phase 2)UnknownNCT05863325
What this trial is testing

Compare the Efficacy and Safety of HB1801 to Taxotere in Advanced Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 80
Large-scale testing (Phase 3)Looking for participantsNCT06350097
What this trial is testing

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
AstraZeneca 582
Early research (Phase 1)Study completedNCT02300298
What this trial is testing

Nintedanib Plus Docetaxel in Japanese Patients With Adenocarcinoma Subtype Non-small Cell Lung Cancer After Failure of First Line Chemotherapy

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim 10
Next Page